Description
ARA-290 (also known as Cibinetide) is an 11-amino-acid synthetic peptide derived from the helix B region of erythropoietin (EPO), specifically engineered as a non-erythropoietic EPO analog that retains binding to the innate repair receptor (IRR / EPOR-CD131 heterocomplex) without activating the classical EPO receptor that drives erythropoiesis. The compound was developed by Araim Pharmaceuticals as a research and clinical candidate for tissue-protective EPO pharmacology research, with academic literature investigating EPOR-CD131 receptor binding, anti-apoptotic signaling cascades, and tissue cell biology endpoints in preclinical research models (Brines, Cerami, and colleagues). ARA-290 is one of the few publicly available non-erythropoietic EPO-derived peptide research tools and is used primarily for innate repair receptor pharmacology and structure-activity relationship (SAR) studies of EPO-helix-B-derived peptides. The compound has undergone clinical trial investigation for several research indications, though it remains an investigational research compound without approved status in major markets.
Benefits (Research Focus)
• EPOR-CD131 receptor pharmacology — studied as a selective innate repair receptor agonist without classical EPO receptor activation
• Non-erythropoietic EPO research — investigated for tissue-protective EPO pharmacology without hematopoietic stimulation
• Anti-apoptotic signaling research — explored for cellular survival pathway endpoints in cell research models
• EPO helix-B SAR research — examined for structure-activity relationships of EPO-helix-B-derived peptide analogs
• Comparative peptide pharmacology — researched alongside other EPO-derived research peptides for receptor selectivity studies
What Researchers Look At
• EPOR / CD131 heterocomplex receptor binding affinity and selectivity profiles
• Differential binding versus classical EPO receptor (EPOR homodimer)
• Anti-apoptotic signaling cascades (JAK/STAT, PI3K/Akt) in cell research models
• Cellular viability and protective signaling endpoints in tissue cell research
• Comparative pharmacology versus full-length erythropoietin and other EPO-derived peptides
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 20 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: ARA-290 (Cibinetide)
• Synonyms: Cibinetide; Helix B Surface Peptide (HBSP); non-erythropoietic EPO analog
• Class: Synthetic 11-amino-acid peptide; EPO helix-B-derived research analog; innate repair receptor agonist
• Sequence: Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (QEQLERALNSS) — 11 amino acids (verify N-terminal form against batch COA; pyroglutamate cyclization possible)
• Origin: Developed by Araim Pharmaceuticals as a non-erythropoietic erythropoietin analog
• Formula / M.W.: ~1178 g/mol (verify exact formula against batch COA — varies with N-terminal cyclization status)
• CAS: 873436-91-0
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• ARA-290 VPeptide Canada — December 4, 2025
